BCL9L and cholangiocarcinoma: Thus, we overexpressed miR-424-5p or knocked down BCL9L in gemcitabine-resistant CCA cells, then evaluated for gemcitabine tolerance, cell apoptosis, sphere formation, transwell cell migration and invasion, and Wnt/β-Catenin activation.